Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenzhen Geno-Immune Medical Institute prostate cancer dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This autologous dendritic cell-based vaccine is an investigational immunotherapy developed by the Shenzhen Geno-Immune Medical Institute for the treatment of prostate cancer. The vaccine is produced by isolating a patient's own dendritic cells and loading them with multiple tumor-associated antigens, derived from either tumor lysates or synthetic peptides. These matured and activated dendritic cells are then administered back to the patient via subcutaneous injection to present these antigens to T cells, thereby stimulating a targeted anti-tumor immune response and establishing long-term immunological memory against prostate cancer cells. It is currently being evaluated in Phase 1/2 clinical trials to assess safety and efficacy in patients with prostate cancer.
- Other names
- Prostate Cancer Dendritic Cell VaccinesImmunomodulatory DC vaccines to target prostate cancer
Beyond the preview
Go deeper on Shenzhen Geno-Immune Medical Institute prostate cancer dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen Geno-Immune Medical Institute prostate cancer dendritic cell vaccine.